Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT02095132 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

76

Enrollment

NIH

Sponsor class

Conditions

Central Nervous System Embryonal Tumor With Rhabdoid Features
Central Nervous System Embryonal Tumor, Not Otherwise Specified
Central Nervous System Ganglioneuroblastoma
Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
Pineoblastoma
Primary Central Nervous System Neoplasm
Recurrent Childhood Central Nervous System Embryonal Neoplasm
Recurrent Malignant Solid Neoplasm
Recurrent Medulloblastoma
Recurrent Neuroblastoma
Recurrent Rhabdomyosarcoma
Refractory Malignant Solid Neoplasm
Refractory Medulloblastoma
Refractory Neuroblastoma
Refractory Rhabdomyosarcoma

Interventions

DRUG: Adavosertib
DRUG: Irinotecan Hydrochloride

Sponsor

National Cancer Institute (NCI)